ARTICLE | Clinical News
VT-1161: Additional Ph IIb RENOVATE data
January 13, 2017 7:53 PM UTC
Additional data from the double-blind, U.S. Phase IIb RENOVATE trial in 259 patients with distal lateral subungual onychomycosis of the large toenail showed that 300 and 600 mg doses of oral VT-1161 o...
BCIQ Company Profiles
BCIQ Target Profiles